Press Releases

Date Title and Summary Additional Formats
Toggle Summary GSK Announces CHMP Positive Opinion for Labelling Update to Relvar Ellipta in Patients with Asthma
LONDON & BRISBANE, Calif. --(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending a label update for the use
View HTML
Toggle Summary Innoviva and Sarissa Implement Court Order
Appoints George Bickerstaff , III and Odysseas Kostas , M.D. to the Board BRISBANE, Calif. --(BUSINESS WIRE)-- Innoviva, Inc. (the "Company" or " Innoviva") (NASDAQ: INVA) today announced it implemented the Delaware Court of Chancery's order enforcing the oral settlement agreement with Sarissa
View HTML
Toggle Summary GSK Submits Landmark IMPACT Data to US Regulatory Authority to Support Expanded Label for Trelegy Ellipta
LONDON & BRISBANE, Calif. --(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/ NYSE : GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the filing of a supplemental New Drug Application (sNDA) with the US Food and Drug Administration (FDA) for the use of Trelegy Ellipta (fluticasone
View HTML
Toggle Summary Trelegy Ellipta Once-Daily Single Inhaler Triple Therapy Gains Marketing Authorisation in Europe for the Treatment of COPD
LONDON & BRISBANE, Calif. --(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/ NYSE : GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Commission has granted marketing authorisation for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol, ‘FF/UMEC/VI') as a maintenance
View HTML
Toggle Summary Innoviva to Participate at the Credit Suisse and Stifel Annual Healthcare Conferences in November
BRISBANE, Calif. --(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) today announced that management will present at the following healthcare-focused investment banking conferences in November 2017 : Credit Suisse 26th Annual Healthcare Conference November 8, 2017 at 12:20 pm MT Scottsdale, Arizona
View HTML
Toggle Summary GSK Study Demonstrates Superiority of Anoro Ellipta to Stiolto Respimat in Improving Lung Function in Chronic Obstructive Pulmonary Disease
LONDON --(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/ NYSE : GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced positive data from a study comparing a once-daily long-acting muscarinic antagonist (LAMA) and a long-acting beta agonist (LABA) fixed-dose combination, Anoro Ellipta
View HTML
Toggle Summary Innoviva Reports Third Quarter 2017 Financial Results and Provides Business Updates
Royalties earned in the third quarter of 2017 of $51.9 million , up 42% from the third quarter of 2016. Completed the full refinancing of the 9% non-recourse term notes due 2029. Plans to repurchase up to $80 million of common stock, pursuant to an accelerated share repurchase (ASR) plan, which
View HTML
Toggle Summary Innoviva to Report Third Quarter Financial Results on October 25 at 5:00 p.m. EDT
BRISBANE, Calif. --(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) announced today that it will report financial results for the third quarter ended September 30, 2017 after market close on Wednesday, October 25, 2017 . Following the earnings release, Innoviva management will host a webcast and
View HTML
Toggle Summary Innoviva to Participate in Cantor Fitzgerald's Global Healthcare Conference on September 26
BRISBANE, Calif. --(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W. Aguiar, Innoviva's President and Chief Executive Officer and Eric d'Esparbes, SVP and Chief Financial Officer will present at the Cantor Fitzgerald Global Healthcare Conference on Tuesday, September
View HTML
Toggle Summary GSK and Innoviva Report Positive Headline Results from IMPACT Study Showing Single Inhaler Triple Therapy Trelegy Ellipta Reduced COPD Exacerbations
Trelegy Ellipta met study primary endpoint demonstrating reduction in exacerbations compared with the dual therapies Anoro Ellipta and Relvar/Breo Ellipta in patients with COPD LONDON --(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/ NYSE : GSK) and Innoviva, Inc.
View HTML

Copyright Nasdaq. Minimum 15 minutes delayed.

Contact

Innoviva Investor Relations & Media
650.238.9640

For business development inquiries,
please contact bd@inva.com.